The European Laboratory Research & Innovation Group (ELRIG) will hold its inaugural US conference on drug discovery in 2025, marking a strategic expansion into North America, the organization announced Tuesday. The event, slated for Boston, aims to bridge European and American pharmaceutical research networks amid growing transatlantic collaboration in biotech.
ELRIG, a nonprofit known for its UK-based forums, plans to feature 150+ speakers across translational medicine, AI-driven drug development, and oncology innovation. Analysts note the timing aligns with increased US federal funding for preclinical research. “This is a natural progression given the shared challenges in accelerating drug pipelines,” said a spokesperson for a Tier 1 pharmaceutical firm, speaking anonymously due to lack of authorization.
The conference will prioritize open-access content, continuing ELRIG’s model of free attendance for academics. Sources familiar with the planning indicate 40% of sessions will focus on CRISPR and RNA therapeutics—areas where US labs lead global patent filings. A draft agenda seen by SourceRated includes workshops with FDA representatives on regulatory harmonization.
Industry observers suggest the move could pressure competing US conferences to adopt similar cost structures. However, some question whether ELRIG’s European-centric approach will resonate domestically. “The real test is whether they can attract Big Pharma’s top R&D teams away from established American events,” noted a Bloomberg Intelligence analyst.